Wed, 09 Feb 2011
Optimer/Astellas: licensing deal set to broaden fidaxomicin's reach
...statistically superior to vancomycin in achieving cure without recurrence and in reducing recurrences of CDI by up to 47%. Optimer has filed marketing applications for fidaxomicin in the US and the EU
Under the terms of the deal, Optimer will receive an upfront payment of $68m and is also eligible to receive further milestone payments totaling approximately $156m, as well as tiered double-digit royalties on sales of the drug upon regulatory approval. Astellas will be responsible for all costs associated with the development, manufacturing, and marketing of fidaxomicin in the territories covered by the deal.
http://www.tradingmarkets.com/news/stock-alert/alpmf_optr_optimer/astellas-licensing-deal-set-to-broaden-fidaxomicin-s-reach-1480205.html